Table of Content

1 Key Insights

2 Glioblastoma Multiforme Market Overview at a Glance
2.1 Market Share (%) Distribution of GBM in 2017
2.2 Market Share (%) Distribution of GBM in 2030

3 Executive Summary of Glioblastoma Multiforme (GBM)

4 Disease Background and Overview: Glioblastoma Multiforme (GBM)
4.1 Introduction
4.2 Classification of Glioblastoma Multiforme
4.3 Glioblastoma Types
4.3.1 Astrocytomas
4.3.2 Ependymomas
4.3.3 Oligodendrogliomas
4.3.4 Mixed gliomas
4.3.5 Optic pathway gliomas
4.4 Symptoms
4.5 Pathophysiology
4.5.1 Macroscopic and Histological Features of GBM
4.5.2 Genetic and Molecular Pathogenesis
4.6 Inheritance of Glioblastoma Multiforme
4.6.1 Genetic Variations of Glioblastoma Multiforme
4.7 Molecular Classification
4.7.1 Specific Molecular Biomarkers
4.8 Diagnosis of Glioblastoma Multiforme
4.8.1 Neurological Exams
4.8.2 Angiograms
4.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)
4.8.4 Perfusion MRI
4.8.5 MR spectroscopy
4.8.6 Histological Diagnosis
4.8.7 Surgical Biopsy
4.9 Glioblastoma in Nut Shell

5 Epidemiology and Patient Population
5.1 Key Findings
5.2 7MM Total Diagnosed Incident Patient Population of Glioblastoma Multiforme

6 Country Wise-Epidemiology of Glioblastoma Multiforme
6.1 United States
6.1.1 Assumptions and Rationale
6.1.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States
6.1.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
6.1.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
6.1.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
6.1.6 Diagnosed Incident Population based on Primary Site of GBM in the United States
6.1.7 Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States
6.2 EU5 Countries
6.2.1 Assumptions and Rationale
6.3 Germany
6.3.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany
6.3.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
6.3.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
6.3.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
6.3.5 Diagnosed Incident Population based on Primary Site of GBM in Germany
6.3.6 Diagnosed Incident Population based on Histologic Classification of GBM in Germany
6.4 France
6.4.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in France
6.4.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France
6.4.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France
6.4.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France
6.4.5 Diagnosed Incident Population based on Primary Site of GBM in France
6.4.6 Diagnosed Incident Population based on Histologic Classification of GBM in France
6.5 Italy
6.5.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy
6.5.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
6.5.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
6.5.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
6.5.5 Diagnosed Incident Population based on Primary Site of GBM in Italy
6.5.6 Diagnosed Incident Population based on Histologic Classification of GBM in Italy
6.6 Spain
6.6.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain
6.6.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
6.6.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
6.6.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
6.6.5 Diagnosed Incident Population based on Primary Site of GBM in Spain
6.6.6 Diagnosed Incident Population based on Histologic Classification of GBM in Spain
6.7 United Kingdom
6.7.1 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom
6.7.2 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
6.7.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
6.7.4 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
6.7.5 Diagnosed Incident Population based on Primary Site of GBM in the United Kingdom
6.7.6 Diagnosed Incident Population based on Histologic Classification of GBM in the United Kingdom
6.8 Japan
6.8.1 Assumptions and Rationale
6.8.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan
6.8.3 Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
6.8.4 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
6.8.5 Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
6.8.6 Diagnosed Incident Population based on Primary Site of GBM in Japan
6.8.7 Diagnosed Incident Population based on Histologic Classification of GBM in Japan

7 Treatment
7.1 Surgery
7.2 Chemotherapy
7.3 Radiation
7.4 Others
7.4.1 Targeted therapy
7.4.2 Tumor treatment fields (TTF)
7.4.3 Immunotherapy
7.5 Management of Symptoms with Medication

8 Treatment Algorithm

9 The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

10 The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

11 Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
11.1 Medical Management and Supportive Care
11.2 Standard Therapy
11.3 Surgical Management
11.4 Radiotherapy Considerations
11.5 Recurrent Glioblastoma Scenario

12 SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

13 Recognized Establishments

14 Unmet Needs

15 Marketed Drugs
1.1 Avastin: Genentech
1.1.1 Drug Description
1.1.2 Regulatory Milestones
1.1.3 Other Development Activities
1.1.4 Safety and Efficacy
1.1.5 Product Profile
1.2 Temodar/Temodal: Merck
1.2.1 Drug Description
1.2.2 Regulatory Milestones
1.2.3 Other Development Activities
1.2.4 Safety and Efficacy
1.2.5 Product Profile

16 Emerging Drugs
16.1 Key Cross Competition
16.2 Other emerging therapies in development
16.3 Ofranergene obadenovec (VB-111): VBL Therapeutics
16.3.1 Product Description
16.3.2 Clinical Development
16.3.3 Safety and Efficacy
16.4 Trans Sodium Crocetinate: Diffusion Pharmaceuticals
16.4.1 Product Description
16.4.2 Clinical Development
16.4.3 Safety and Efficacy
16.5 Regorafenib: Bayer
16.5.1 Product Description
16.5.2 Clinical Development
16.5.3 Safety and Efficacy
16.6 Durvalumab (MEDI4736): MedImmune
16.6.1 Product Description
16.6.2 Clinical Development
16.6.3 Safety and Efficacy
16.7 Tasadenoturev (DNX-2401): DNAtrix
16.7.1 Product Description
16.7.2 Clinical Development
16.7.3 Safety and Efficacy
16.8 ONC201: Oncoceutics
16.8.1 Product Description
16.8.2 Clinical Development
16.8.3 Safety and Efficacy
16.9 Selinexor (KPT-330): Karyopharm Therapeutics
16.9.1 Product Description
16.9.2 Clinical Development
16.9.3 Safety and Efficacy
16.1 VBI-1901: VBI Vaccines
16.10.1 Product Description
16.10.2 Clinical Development
16.10.3 Safety and Efficacy
16.11 Paxalisib (GDC-0084): Kazia Therapeutics
16.11.1 Product Description
16.11.2 Clinical Development
16.11.3 Safety and Efficacy
16.12 AV-GBM-1: Aivita Biomedical
16.12.1 Product Description
16.12.2 Clinical Development
16.12.3 Safety and Efficacy
16.13 MDNA55: Medicenna Therapeutics
16.13.1 Product Description
16.13.2 Clinical Development
16.13.3 Safety and Efficacy
16.14 VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals
16.14.1 Product Description
16.14.2 Clinical Development
16.14.3 Safety and Efficacy
16.15 ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
16.15.1 Product Description
16.15.2 Clinical Development
16.15.3 Safety and Efficacy
16.16 INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
16.16.1 Product Description
16.16.2 Clinical Development
16.16.3 Safety and Efficacy
17 Glioblastoma Multiforme: 7 Major Market Analysis
17.1 Key Findings
17.2 Total Market Size of Glioblastoma Multiforme in the 7 MM
17.3 The United States Market Outlook
17.4 United States Market Size
17.4.1 Total Market size of Glioblastoma Multiforme in the United States
17.4.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.4.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
17.5 EU-5 Countries: Market Outlook
17.6 Germany
17.6.1 Total Market size of Glioblastoma Multiforme in Germany
17.6.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.6.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
17.7 France
17.7.1 Total Market Size of Glioblastoma Multiforme in France
17.7.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.7.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
17.8 Italy
17.8.1 Total Market Size of Glioblastoma Multiforme in Italy
17.8.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.8.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
17.9 Spain
17.9.1 Total Market Size of Glioblastoma Multiforme in Spain
17.9.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.9.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
17.1 United Kingdom
17.10.1 Total Market Size of Glioblastoma Multiforme in the United Kingdom
17.10.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.10.3 Market Size of Glioblastoma Multiforme by Emerging Therapies
17.11 Japan: Market Outlook
17.11.1 Total Market Size of Glioblastoma Multiforme in Japan
17.11.2 Market Size of Glioblastoma Multiforme by Current Therapies
17.11.3 Market Size of Glioblastoma Multiforme by Emerging Therapies

18 Market Access and Reimbursement
18.1 United States
18.2 Europe
18.3 Japan

19 Case Reports
19.1 Glioblastoma and intracranial aneurysms: Case report and review of the literature (United States)
19.2 A New Method for Ethical and Efficient Evidence Generation for Off-label Medication Use in Oncology (A Case Study in Glioblastoma) (United Kingdom)
19.3 Diagnosis and treatment of early-stage glioblastoma (Japan)

20 KOL Reviews

21 Market Drivers

22 Market Barriers

23 SWOT Analysis

24 Appendix
24.1 Bibliography
24.2 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight



List of Figures


Figure 1: Classification of Glioblastoma
Figure 2: Different types of Glioblastoma
Figure 3: Generalized transcription pathways related to Glioblastoma disease
Figure 4: Up-regulated Genetic Pathways in Glioblastoma
Figure 5: Overall pathways of IDH mutations
Figure 6: Chemistry of O6-Methylguanine-DNA Methyltransferase (MGMT)
Figure 7: Functioning of MicroRNA as a biomarker in Glioblastoma
Figure 8: Total Diagnosed Incident Patient Population of GBM in the 7MM (2017–2030)
Figure 9: Total Diagnosed Incident Population of Glioblastoma Multiforme in the US (2017–2030)
Figure 10: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017–2030)
Figure 11: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017–2030)
Figure 12: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the US (2017–2030)
Figure 13: Diagnosed Incident Population based on Primary Site of GBM Tumor in the US (2017–2030)
Figure 14: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the US (2017–2030)
Figure 15: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2017–2030)
Figure 16: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)
Figure 17: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)
Figure 18: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)
Figure 19: Diagnosed Incident Population based on Primary Site of GBM Tumor in Germany (2017–2030)
Figure 20: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Germany (2017–2030)
Figure 21: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2017–2030)
Figure 22: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)
Figure 23: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)
Figure 24: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)
Figure 25: Diagnosed Incident Population based on Primary Site of GBM Tumor in France (2017–2030)
Figure 26: Diagnosed Incidence based on Histologic Classification of GBM Tumor in France (2017–2030)
Figure 27: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2017–2030)
Figure 28: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)
Figure 29: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)
Figure 30: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)
Figure 31: Diagnosed Incident Population based on Primary Site of GBM Tumor in Italy (2017–2030)
Figure 32: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Italy (2017–2030)
Figure 33: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2017–2030)
Figure 34: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)
Figure 35: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)
Figure 36: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)
Figure 37: Diagnosed Incident Population based on Primary Site of GBM Tumor in Spain (2017–2030)
Figure 38: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Spain (2017–2030)
Figure 39: Total Diagnosed Incident Population of Glioblastoma Multiforme in the UK (2017–2030)
Figure 40: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017–2030)
Figure 41: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017–2030)
Figure 42: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017–2030)
Figure 43: Diagnosed Incident Population based on Primary Site of GBM Tumor in the UK (2017–2030)
Figure 44: Diagnosed Incidence based on Histologic Classification of GBM Tumor in the UK (2017–2030)
Figure 45: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2017–2030)
Figure 46: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)
Figure 47: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)
Figure 48: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)
Figure 49: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2017–2030)
Figure 50: Diagnosed Incidence based on Histologic Classification of GBM Tumor in Japan (2017–2030)
Figure 51: NCCN Guidelines for treatment of Anaplastic Gliomas/Glioblastoma
Figure 52: NCCN Guidelines for Treatment of Recurrent Anaplastic Gliomas/Glioblastoma
Figure 53: Unmet Needs of Glioblastoma
Figure 54: Total 7 Major Market Size of Glioblastoma Multiforme in USD Million (2017–2030)
Figure 55: Total Market Size of GBM in the United States, USD Millions (2017–2030)
Figure 56: Market size of GBM by Current Therapies in the US, in USD Million (2017–2030)
Figure 57: Market size of GBM by Emerging Therapies in the US, in USD Million (2017–2030)
Figure 58: Total Market Size of Glioblastoma Multiforme in Germany, USD Million (2017–2030)
Figure 59: Market size of GBM by Current Therapies in Germany, in USD Million (2017–2030)
Figure 60: Market size of GBM by Emerging Therapies in Germany, in USD Million (2017–2030)
Figure 61: Total Market Size of Glioblastoma Multiforme in France, USD Million (2017–2030)
Figure 62: Market size of GBM by Current Therapies in France, in USD Million (2017–2030)
Figure 63: Market size of GBM by Emerging Therapies in France, in USD Million (2017–2030)
Figure 64: Total Market Size of Glioblastoma Multiforme in Italy, USD Million (2017–2030)
Figure 65: Market size of Glioblastoma Multiforme by Current Therapies in Italy, in USD Million (2017–2030)
Figure 66: Market size of GBM by Emerging Therapies in Italy, in USD Million (2017–2030)
Figure 67: Total Market Size of Glioblastoma Multiforme in Spain, USD Million (2017–2030)
Figure 68: Market size of Glioblastoma Multiforme by Current Therapies in Spain, in USD Million (2017–2030)
Figure 69: Market size of GBM by Emerging Therapies in Spain, in USD Million (2017–2030)
Figure 70: Total Market Size of GBM in the United Kingdom, USD Million (2017–2030)
Figure 71: Market size of GBM by Current Therapies in the UK, in USD Million (2017–2030)
Figure 72: Market size of GBM by Emerging Therapies in the UK, in USD Million (2017–2030)
Figure 73: Total Market Size of Glioblastoma Multiforme in Japan, USD Million (2017–2030)
Figure 74: Market size of Glioblastoma Multiforme by Current Therapies in Japan, in USD Million (2017–2030)
Figure 75: Market size of GBM by Emerging Therapies in Japan, in USD Million (2017–2030)
Figure 76: Market Drivers
Figure 77: Market Barriers
Figure 78: SWOT Analysis


List of Tables


Table 1: Summary of Glioblastoma Multiforme, Market, Epidemiology and Key Events (2017–2030)
Table 2: Total Diagnosed Incident Patient Population of Glioblastoma Multiforme in the 7MM (2017–2030)
Table 3: Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States (2017–2030)
Table 4: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017–2030)
Table 5: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017–2030)
Table 6: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017–2030)
Table 7: Diagnosed Incident Population based on Primary Site of GBM Tumor in the United States (2017–2030)
Table 8: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States (2017–2030)
Table 9: Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany (2017–2030)
Table 10: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)
Table 11: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)
Table 12: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017–2030)
Table 13: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Germany (2017–2030)
Table 14: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Germany (2017–2030)
Table 15: Total Diagnosed Incident Population of Glioblastoma Multiforme in France (2017–2030)
Table 16: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)
Table 17: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)
Table 18: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017–2030)
Table 19: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in France (2017–2030)
Table 20: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in France (2017–2030)
Table 21: Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy (2017–2030)
Table 22: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)
Table 23: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)
Table 24: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017–2030)
Table 25: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Italy (2017–2030)
Table 26: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Italy (2017–2030)
Table 27: Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain (2017–2030)
Table 28: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)
Table 29: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)
Table 30: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017–2030)
Table 31: Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in Spain (2017–2030)
Table 32: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Spain (2017–2030)
Table 33: Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom (2017–2030)
Table 34: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017–2030)
Table 35: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017–2030)
Table 36: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017–2030)
Table 37:Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme Tumor in the UK (2017–2030)
Table 38: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United Kingdom (2017–2030)
Table 39: Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan (2017–2030)
Table 40: Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)
Table 41: Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)
Table 42: Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017–2030)
Table 43: Diagnosed Incident Population based on Primary Site of GBM Tumor in Japan (2017–2030)
Table 44: Diagnosed Incident Population based on Histologic Classification of GBM Tumor in Japan (2017–2030)
Table 45: Adjuvant Treatment of Glioblastoma based on Age and Karnofsky Performance Status
Table 46: Summary of recommendations
Table 47: Comparison of emerging drugs under development
Table 48: Comparison of emerging drugs under development
Table 49: VB-111, Clinical Trial Description, 2020
Table 50: Trans Sodium Crocetinate, Clinical Trial Description, 2020
Table 51: Regorafenib, Clinical Trial Description, 2020
Table 52: Durvalumab, Clinical Trial Description, 2020
Table 53: Tasadenoturev (DNX-2401), Clinical Trial Description, 2020
Table 54: ONC201, Clinical Trial Description, 2020
Table 55: Selinexor (KPT-330), Clinical Trial Description, 2020
Table 56: VBI-1901, Clinical Trial Description, 2020
Table 57: Paxalisib (GDC-0084), Clinical Trial Description, 2020
Table 58: AV-GBM-1, Clinical Trial Description, 2020
Table 59: MDNA55, Clinical Trial Description, 2020
Table 60: VAL-083 (Dianhydrogalactitol), Clinical Trial Description, 2020
Table 61: pp65 DC Vaccine, Clinical Trial Description, 2020
Table 62: INO-5401+ INO-9012+ Cemiplimab (REGN2810), Clinical Trial Description, 2020
Table 63: Total 7 Major Market Size of Glioblastoma Multiforme in USD Million (2017–2030)
Table 64: Total Market Size of Glioblastoma Multiforme in the United States, in USD Million (2017–2030)
Table 65: Market size of Glioblastoma Multiforme by Current Therapies in the United States, in USD Million (2017–2030)
Table 66: Market size of Glioblastoma Multiforme by Emerging Therapies in the United States, in USD Million (2017–2030)
Table 67: Total Market Size of Glioblastoma Multiforme in Germany, in USD Million (2017–2030)
Table 68: Market size of Glioblastoma Multiforme by Current Therapies in Germany, in USD Million (2017–2030)
Table 69: Market size of Glioblastoma Multiforme by Emerging Therapies in Germany, in USD Million (2017–2030)
Table 70: Total Market Size of Glioblastoma Multiforme in France, in USD Million (2017–2030)
Table 71: Market size of Glioblastoma Multiforme by Current Therapies in France, in USD Million (2017–2030)
Table 72: Market size of Glioblastoma Multiforme by Emerging Therapies in France, in USD Million (2017–2030)
Table 73: Total Market Size of Glioblastoma Multiforme in Italy, in USD Million (2017–2030)
Table 74: Market size of Glioblastoma Multiforme by Current Therapies in Italy, in USD Million (2017–2030)
Table 75: Market size of Glioblastoma Multiforme by Emerging Therapies in Italy, in USD Million (2017–2030)
Table 76: Total Market Size of Glioblastoma Multiforme in Spain, in USD Million (2017–2030)
Table 77: Market size of Glioblastoma Multiforme by Current Therapies in Spain, in USD Million (2017–2030)
Table 78: Market size of Glioblastoma Multiforme by Emerging Therapies in Spain, in USD Million (2017–2030)
Table 79: Total Market Size of Glioblastoma Multiforme in the United Kingdom, in USD Million (2017–2030)
Table 80: Market size of Glioblastoma Multiforme by Current Therapies in the United Kingdom, in USD Million (2017–2030)
Table 81: Market size of Glioblastoma Multiforme by Emerging Therapies in the UK, in USD Million (2017–2030)
Table 82: Total Market Size of Glioblastoma Multiforme in Japan, in USD Million (2017–2030)
Table 83: Market size of Glioblastoma Multiforme by Current Therapies in Japan, in USD Million (2017–2030)
Table 84:Market size of Glioblastoma Multiforme by Emerging Therapies in Japan, in USD Million (2017–2030)